Plasma levels of norethindrone and effect upon ovarian function during treatment with silastic implants containing norethindrone.
The study was made to evaluate the effect upon the ovarian steroid pattern during treatment with subcutaneously implanted silastic rods containing norethindrone. Four rods, each containing 37 mg norethindrone (NET), were implanted subcutaneously in five women and left in place for 135--200 days. Plasma levels of NET, estradiol and progesterone were determined by radioimmunoassays. After an initial peak found in all subjects, the plasma level of NET declined. Great day-to-day variations of NET were found. Ovulations were suppressed during treatment in three subjects. One subject had regular ovulations throughout treatment and in one subject a single ovulation was recorded. Peaks of estradiol without subsequent ovulation were found in two subjects. The bleeding pattern was irregular; three subjects had varying degrees of spotting and bleeding, two subjects were amenorrheic. The average daily release rate was 300/micrograms, calculated from the amount of steroids lost from the removed rods. This study indicates that the release of steroid from four NET rods is high enough only initially to completely inhibit ovulation.
D000328:Adult; D004343:Drug Implants; D004958:Estradiol / Q000097:blood*; D005260:Female; D006801:Humans; D009640:Norethindrone / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood*
D004343:Drug Implants; D011374:Progesterone; D004958:Estradiol; D009640:Norethindrone